New: Connect your wearable. Get a peptide protocol tuned to your data.

Stacks

CagriSema (Cagrilintide / Semaglutide) Stack

A co-formulated metabolic research blend pairing cagrilintide — a long-acting amylin analog — with semaglutide, a GLP-1 receptor agonist, in a single vial. The dual amylin-plus-GLP-1 approach was studied in Novo Nordisk's Phase 3 REDEFINE program, where the combination produced greater weight reduction than either component alone. Semaglutide is FDA-approved only as a specific finished drug; the bulk peptide and this combination are unapproved and provided strictly as a chemical reagent for laboratory research use only.

Studied Benefits

  • Pairs amylin (cagrilintide) and GLP-1 (semaglutide) research pathways in one vial
  • Dual satiety mechanisms studied in the Phase 3 REDEFINE program
  • Combination showed greater weight reduction than either compound alone in trials
  • Investigational combination — research use only, no approved co-formulation exists

Research Use Only

This compound is intended for laboratory and research purposes only. It is not approved for human consumption and is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional.

Full Research Guide

Independently Reviewed

We only list vendors that provide third-party, batch-specific COAs.

PSPeptides

Use code AURAPRO10 for 10% off

Buy Direct from PSPeptides

Affiliate disclosure: links above are affiliate partnerships. We may earn a commission at no cost to you.

Make this protocol yours

The Engine reads your biometrics and personalizes dosing, timing, and stacking — free at engine.auraprotocols.com.

Try the Engine →